Dr. GPCR Ecosystem
Time is your enemy, GPCR's are your friends
Abstract
We all know that 2020 was a year like no other. However around this time, another global shift in biology occurred, for the first time in human history, there were more people aged over 65 compared to under 5. This global aging shift will make age-related disorders more and more important for therapeutic developers. In my Virtual Cafe, I will discuss how for the last decade my lab has pioneered the investigation of how an aging physiological context affects G protein-coupled receptor (GPCR) signaling. With this new knowledge, our next goal is to generate novel therapeutics that can potentially stem the development of aging-related disorders before the presentation of severe disease. Our investigations into the aging context of GPCR signaling have revealed the hidden true complexity and range of signaling of this most versatile drug target.
About Dr. Stuart Maudsley
"I am currently the Odysseus Professor of Receptor Pharmacology at the University of Antwerp in Belgium. I received my Ph.D. in receptor pharmacology at the University of Leeds as the Ackroyd Brotherton and Brown Scholar of the University. During my Ph.D., I developed some of the first concepts of β-arrestin-dependent signaling. Following my Ph.D., I was awarded a Howard Hughes Fellowship to work with Prof. Robert Lefkowitz at Duke University where I continued my research into how diverse signaling molecules can modify the signaling output of G protein-coupled receptors. Following my fellowship at Duke, I was recruited to be a Principal Investigator at the Medical Research Council (MRC) Human Reproductive Sciences Unit at the University of Edinburgh.
After developing several context-specific anti-cancer receptor-based therapeutics I moved to the United States to be the Head of the Receptor Pharmacology Unit at the NIH-National Institute on Aging at Johns Hopkins Medical School. At the NIH my lab investigated how GPCR signaling is conditioned and controlled by the hyper-complex aging process. I am now in the process of developing my lab’s new translational therapeutic GPCR company, HeptOME. HeptOME aims to develop/refine GPCR therapeutics for aging-related disorders including cancers, diabetes, and cardiovascular disorders."
Dr. Stuart Maudsley on the web
